SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Håkan Widner) "

Sökning: WFRF:(Håkan Widner)

  • Resultat 31-40 av 96
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Huttunen, Henri J., et al. (författare)
  • Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial
  • 2023
  • Ingår i: Movement Disorders. - : John Wiley & Sons. - 0885-3185 .- 1531-8257. ; 38:7, s. 1209-1222
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Cerebral dopamine neurotrophic factor (CDNF) is an unconventional neurotrophic factor that protects dopamine neurons and improves motor function in animal models of Parkinson's disease (PD). Objective: The primary objectives of this study were to assess the safety and tolerability of both CDNF and the drug delivery system (DDS) in patients with PD of moderate severity. Methods: We assessed the safety and tolerability of monthly intraputamenal CDNF infusions in patients with PD using an investigational DDS, a bone-anchored transcutaneous port connected to four catheters. This phase 1 trial was divided into a placebo-controlled, double-blind, 6-month main study followed by an active-treatment 6-month extension. Eligible patients, aged 35 to 75 years, had moderate idiopathic PD for 5 to 15 years and Hoehn and Yahr score ≤ 3 (off state). Seventeen patients were randomized to placebo (n = 6), 0.4 mg CDNF (n = 6), or 1.2 mg CDNF (n = 5). The primary endpoints were safety and tolerability of CDNF and DDS and catheter implantation accuracy. Secondary endpoints were measures of PD symptoms, including Unified Parkinson's Disease Rating Scale, and DDS patency and port stability. Exploratory endpoints included motor symptom assessment (PKG, Global Kinetics Pty Ltd, Melbourne, Australia) and positron emission tomography using dopamine transporter radioligand [18F]FE-PE2I. Results: Drug-related adverse events were mild to moderate with no difference between placebo and treatment groups. No severe adverse events were associated with the drug, and device delivery accuracy met specification. The severe adverse events recorded were associated with the infusion procedure and did not reoccur after procedural modification. There were no significant changes between placebo and CDNF treatment groups in secondary endpoints between baseline and the end of the main and extension studies. Conclusions: Intraputamenally administered CDNF was safe and well tolerated, and possible signs of biological response to the drug were observed in individual patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
  •  
32.
  • Johansson, Barbro, et al. (författare)
  • Evaluation of long-term functional status in first-ever stroke patients in a defined population
  • 1992
  • Ingår i: Scandinavian journal of rehabilitation medicine. Supplement. - 0346-8720. ; 26, s. 105-114
  • Tidskriftsartikel (refereegranskat)abstract
    • Medical, social and ADL variables were registered within 48 hours of stroke onset and 6 and 12 months later in 346 first-ever stroke patients. One year after stroke onset 27% of the patients were dead. 78% of the surviving patients were living in their own homes, 10.6% in old people's homes with no medical facilities and 9.5% in nursing homes. A health index was used for ADL evaluation and the quality of life was estimated according to Nottingham Health Profile (NHP). 16% of the patients had domestic social service assistance before stroke onset. The help given by relatives and friends far exceeded that given by the society before as well as after stroke onset. Right hemispheric stroke patients had a worse outcome than left-sided with respect to ADL and life satisfaction.
  •  
33.
  •  
34.
  • Kaufman, Eli, et al. (författare)
  • Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy.
  • 2013
  • Ingår i: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 8:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Despite several lines of evidence from preclinical and post-mortem studies suggesting that inflammation is involved in Multiple System Atrophy (MSA), no previous studies have measured peripheral indices of inflammation in MSA patients.
  •  
35.
  • Kefalopoulou, Zinovia, et al. (författare)
  • Long-term clinical outcome of fetal cell transplantation for Parkinson disease : two case reports
  • 2014
  • Ingår i: JAMA Neurology. - : American Medical Association (AMA). - 2168-6157 .- 2168-6149. ; 71:1, s. 7-83
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE: Recent advances in stem cell technologies have rekindled an interest in the use of cell replacement strategies for patients with Parkinson disease. This study reports the very long-term clinical outcomes of fetal cell transplantation in 2 patients with Parkinson disease. Such long-term follow-up data can usefully inform on the potential efficacy of this approach, as well as the design of trials for its further evaluation.OBSERVATIONS: Two patients received intrastriatal grafts of human fetal ventral mesencephalic tissue, rich in dopaminergic neuroblasts, as restorative treatment for their Parkinson disease. To evaluate the very long-term efficacy of the grafts, clinical assessments were performed 18 and 15 years posttransplantation. Motor improvements gained gradually over the first postoperative years were sustained up to 18 years posttransplantation, while both patients have discontinued, and remained free of any, pharmacological dopaminergic therapy.CONCLUSIONS AND RELEVANCE: The results from these 2 cases indicate that dopaminergic cell transplantation can offer very long-term symptomatic relief in patients with Parkinson disease and provide proof-of-concept support for future clinical trials using fetal or stem cell therapies.
  •  
36.
  • Kirkeby, Agnete, et al. (författare)
  • Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD
  • 2023
  • Ingår i: Cell Stem Cell. - 1934-5909. ; 30:10, s. 1299-1314
  • Tidskriftsartikel (refereegranskat)abstract
    • Cell replacement therapies for Parkinson's disease (PD) based on transplantation of pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting the first-in-human STEM-PD phase I/IIa clinical trial along with the trial design. The STEM-PD product was manufactured under GMP and quality tested in vitro and in vivo to meet regulatory requirements. Importantly, no adverse effects were observed upon testing of the product in a 39-week rat GLP safety study for toxicity, tumorigenicity, and biodistribution, and a non-GLP efficacy study confirmed that the transplanted cells mediated full functional recovery in a pre-clinical rat model of PD. We further observed highly comparable efficacy results between two different GMP batches, verifying that the product can be serially manufactured. A fully in vivo-tested batch of STEM-PD is now being used in a clinical trial of 8 patients with moderate PD, initiated in 2022.
  •  
37.
  • Koellensperger, Martin, et al. (författare)
  • Presentation, Diagnosis, and Management of Multiple System Atrophy in Europe: Final Analysis of the European Multiple System Atrophy Registry
  • 2010
  • Ingår i: Movement Disorders. - : Wiley. - 0885-3185. ; 25:15, s. 2604-2612
  • Tidskriftsartikel (refereegranskat)abstract
    • Multiple system atrophy (MSA) is a Parkinson's Disease (PD)-like alpha-synucleinopathy clinically characterized by dysautonomia, parkinsonism, cerebellar ataxia, and pyramidal signs in any combination. We aimed to determine whether the clinical presentation of MSA as well as diagnostic and therapeutic strategies differ across Europe and Israel. In 19 European MSA Study Group centres all consecutive patients with a clinical diagnosis of MSA were recruited from 2001 to 2005. A standardized minimal data set was obtained from all patients. Four-hundred thirty-seven MSA patients from 19 centres in 10 countries were included. Mean age at onset was 57.8 years; mean disease duration at inclusion was 5.8 years. According to the consensus criteria 68% were classified as parkinsonian type (MSA-P) and 32% as cerebellar type (MSA-C) (probable MSA: 72%, possible MSA: 28%). Symptomatic dysautonomia was present in almost all patients, and urinary dysfunction (83%) more common than symptomatic orthostatic hypotension (75%). Cerebellar ataxia was present in 64%, and parkinsonism in 87%, of all cases. No significant differences in the clinical presentation were observed between the participating countries. In contrast, diagnostic work up and therapeutic strategies were heterogeneous. Less than a third of patients with documented orthostatic hypotension or neurogenic bladder disturbance were receiving treatment. This largest clinical series of MSA patients reported so far shows that the disease presents uniformly across Europe. The observed differences in diagnostic and therapeutic management including lack of therapy for dysautonomia emphasize the need for future guidelines in these areas. (C) 2010 Movement Disorder Society
  •  
38.
  • Koellensperger, Martin, et al. (författare)
  • Red flags for multiple system atrophy
  • 2008
  • Ingår i: Movement Disorders. - : Wiley. - 0885-3185 .- 1531-8257. ; 23:8, s. 1093-1099
  • Tidskriftsartikel (refereegranskat)abstract
    • The clinical diagnosis Of Multiple system atrophy (MSA) is fraught with difficulty and there are no pathognomonic features to discriminate the parkinsonian variant (MSA-P) from Parkinson's disease (PD). Besides the poor response to levodopa, and the additional presence of pyramidal or cerebellar signs (ataxia) or autonomic failure as major diagnostic criteria, certain other clinical features known as "red flags" or warning signs may raise the clinical suspicion of MSA. To study the diagnostic role of these features in MSA-P versus PD patients, a standardized red flag check list (RFCL) developed by the European MSA Study Group (EMSA-SG) was administered to 57 patients with probable MSA-P and 116 patients with probable PD diagnosed according to established criteria. Those red flags with a specifity over 95% were selected for further analysis. Factor analysis was applied to reduce the number of red flags. The resulting set was then applied to 17 patients with possible MSA-P who on follow-up fulfilled criteria of probable MSA-P. Red flags were grouped into related categories. With two or more of six red flag categories present specificity was 98.3% and sensitivity was 84.2% in our cohort. When applying these criteria to patients with possible MSA-P, 76.5% of them would have been correctly diagnosed as probable MSA-P 15.9 (+/- 7.0) months earlier than with the Consensus criteria alone. We propose a combination of two out of six red flag categories as additional diagnostic criteria for probable MSA-P. (C) 2008 Movement Disorder Society.
  •  
39.
  •  
40.
  • Kurowska, Zuzanna, et al. (författare)
  • Signs of Degeneration in 12-22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson's Disease
  • 2011
  • Ingår i: Journal of Parkinson's Disease. - 1877-718X. ; 1:1, s. 83-92
  • Tidskriftsartikel (refereegranskat)abstract
    • We demonstrate that grafted human fetal mesencephalic neurons can survive and extend axons for 22 years in the brain of a patient with Parkinson's disease (PD). In this patient, the overall survival and fiber outgrowth of the grafts were, however, relatively poor, which is consistent with the lack of significant clinical graft-induced benefit. We have compared the morphology of neurons in the 22-year old grafts with those in two younger grafts (16- and 12-year old), which were sequentially implanted in another PD patient. In the case with the 22-year-old transplant, a high proportion (up to 38%) of the grafted dopaminergic (pigment-granule containing) neurons do not express tyrosine hydroxylase and dopamine transporter and their perikarya appear atrophic. The proportion of pigmented neurons not expressing these markers is lower in the 12-16 year old grafts. Furthermore, in the 22-year-old graft, 49% of the pigmented neurons display alpha-synuclein immunoreactivity in the cell body and 1.2% of them contain Lewy bodies. In conclusion, our results show that grafted dopaminergic neurons can survive for more than two decades. However, over time an increasing proportion of grafted neurons exhibit signs of degeneration.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 96
Typ av publikation
tidskriftsartikel (77)
konferensbidrag (12)
annan publikation (3)
forskningsöversikt (3)
bokkapitel (1)
Typ av innehåll
refereegranskat (88)
övrigt vetenskapligt/konstnärligt (7)
populärvet., debatt m.m. (1)
Författare/redaktör
Widner, Håkan (96)
Lindvall, Olle (17)
Rehncrona, Stig (15)
Brundin, Patrik (14)
Björklund, Anders (13)
Nilsson, Christer (11)
visa fler...
Hansson, Oskar (11)
Hagell, Peter (10)
Johansson, Anders (9)
Nyholm, Dag (9)
Odin, Per (9)
van Westen, Danielle (8)
Svenningsson, Per (8)
Puschmann, Andreas (8)
Englund, Elisabet (7)
Hall, Sara (6)
Brooks, D J (6)
Schrag, A (5)
Westin, Jerker (5)
Li, Jia-Yi (5)
Willows, Thomas (5)
Barker, Roger A. (5)
Piccini, Paola (5)
Piccini, P (5)
Linder, Jan (4)
Foltynie, Thomas (4)
Albanese, Alberto (4)
Paul, Gesine (4)
Lätt, Jimmy (4)
Gasser, Thomas (4)
Wictorin, Klas (4)
Nilsson, Markus (3)
Memedi, Mevludin (3)
Bergquist, Filip (3)
Kefalopoulou, Zinovi ... (3)
Ross, Owen A. (3)
Cronberg, Tobias (3)
Friberg, Hans (3)
Lampinen, Björn (3)
Poewe, Werner (3)
Schrag, Anette (3)
Bjartmarz, Hjalmar (3)
Ostergaard, K (3)
Quinn, N P (3)
Klockgether, Thomas (3)
Rascol, Olivier (3)
Wszolek, Zbigniew K. (3)
Quinn, N. (3)
Coelho, Miguel (3)
Seppi, Klaus (3)
visa färre...
Lärosäte
Lunds universitet (82)
Karolinska Institutet (17)
Uppsala universitet (11)
Göteborgs universitet (7)
Umeå universitet (6)
Linköpings universitet (5)
visa fler...
Örebro universitet (4)
Högskolan Dalarna (3)
Högskolan Kristianstad (1)
Jönköping University (1)
Malmö universitet (1)
visa färre...
Språk
Engelska (88)
Svenska (7)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (90)
Teknik (3)
Naturvetenskap (2)
Lantbruksvetenskap (1)
Samhällsvetenskap (1)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy